EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

IL-27 gut immunology: Mechanisms and potential value as a biomarker and therapeutic target in intestinal diseases

Yixuan Han, Suli Wang, Chenyang Li, Shenglan Zhang, Xiaotong Geng, Anna Zheng, Pingxin Zhou, Feng Ren, Qian Wang, Zhinan Yin, Zishan Yang

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yixuan Han und 10 weiteren Autor:innen. Beteiligte Einrichtung: Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, PR…. Hauptthemen laut MEDLINE: Intestinal Mucosa, Interleukin-27, Intestinal Diseases, Inflammatory Bowel Diseases. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Xinxiang Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-27 (IL-27), an Interleukin-12 (IL-12) family heterodimeric cytokine, plays a central yet complex role in immunoregulation within the intestinal mucosa, where its context-dependent actions can promote both protective and pathogenic outcomes. Although its cellular sources, receptor structure (IL-27Rα/gp130 complex), and involvement in regulating key immune cells (e.g., T-cell subsets, macrophages, neutrophils) and epithelial functions are established, the precise mechanisms underlying its paradoxical effects-balancing homeostasis with inflammation-remain incompletely resolved. This review synthesizes current understanding of IL-27 biology to clarify its multifaceted role. Crucial insights into these dual functions have emerged from preclinical models, including murine colitis (e.g., DSS-, TNBS-induced), enteric infection (e.g., Toxoplasma gondii, Citrobacter rodentium), and colorectal cancer models. These studies demonstrate that IL-27 critically orchestrates gut immunity, maintaining homeostasis through antimicrobial defense and barrier enhancement while suppressing immunopathology. Conversely, its dysregulation drives chronic inflammation and carcinogenesis. Clinically, IL-27 expression correlates with disease activity in inflammatory bowel disease (IBD), colorectal cancer (CRC), and infections, highlighting its biomarker potential. Consequently, targeting the IL-27 pathway presents promising therapeutic avenues: augmenting signaling may mitigate IBD hyperinflammation, while inhibition could bolster antitumor immunity or resolve infection-driven pathology. Future research must prioritize defining context-specific IL-27 functions, optimizing delivery strategies, and integrating IL-27 targeting with existing biologics to translate its immunomodulatory potential into novel therapies for intestinal diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal MucosaInterleukin-27Intestinal DiseasesInflammatory Bowel DiseasesInterleukinsAnimalsHumansBiomarkers

Stichwörter der Autor:innen

IL-27Intestinal diseasesT cellsTargeted therapy

Substanzen

BiomarkersInterleukin-27Interleukins

Autor:innen und Institutionen

  • Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, PR China.
  • Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, PR China; Henan Research Center for Engineering Technology in Digestive…
  • Henan Research Center for Engineering Technology in Digestive Tract Tumor Immune Digital Decoding and Cell Therapy, Xinxiang Medical University, Xinxiang, Henan 453000, PR China; Henan International Joint Laboratory of…
  • The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong 510632, PR China. Electronic address: wangqian@jnu.edu.cn.
  • The Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong 510632, PR China. Electronic address: tzhinan@jnu.edu.cn.

Förderung

  • Xinxiang Medical University

Zitieren

APA

Han, Y., Wang, S., Li, C., Zhang, S., Geng, X., Zheng, A., Zhou, P., Ren, F., Wang, Q., Yin, Z., & Yang, Z. (2025). IL-27 gut immunology: Mechanisms and potential value as a biomarker and therapeutic target in intestinal diseases. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115755

Vancouver

Han Y, Wang S, Li C, Zhang S, Geng X, Zheng A, et al. IL-27 gut immunology: Mechanisms and potential value as a biomarker and therapeutic target in intestinal diseases. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115755

BibTeX
@article{Han2025,
  author = {Han, Yixuan and Wang, Suli and Li, Chenyang and Zhang, Shenglan and Geng, Xiaotong and Zheng, Anna and Zhou, Pingxin and Ren, Feng and Wang, Qian and Yin, Zhinan and Yang, Zishan},
  title = {IL-27 gut immunology: Mechanisms and potential value as a biomarker and therapeutic target in intestinal diseases},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115755}
}
Kostenlos starten →